Avenue Therapeutics Inc (ATXI)
OTHER OTC:ATXI
Want to see ATXI full AI Analyst Report?
Top Page
Avenue Therapeutics
(OTC:ATXI)
Select Model
Select Model
Rating:52Neutral
Price Target:
$0.56
▼(-23.84% Downside)
Action:ReiteratedDate:04/26/26
The score is held back primarily by ongoing losses, negative cash flow, and limited balance-sheet capacity despite no debt. Technicals are supportive with clear momentum (price above key moving averages and positive MACD), but elevated RSI/Stoch point to stretched conditions. Valuation is constrained by negative earnings, while the recent positive licensing deal adds a modest strategic lift.
Positive Factors
Pipeline expansion — ATX-04 license
The Duke ATX-04 license supplies a late-stage, mechanism-based asset with an existing IND and orphan designation plus human proof-of-concept data. Structurally this diversifies Avenue beyond tramadol, accelerates regulatory path options and strengthens rare-disease program depth.
Negative Factors
Limited balance-sheet capacity
Modest assets and a small, declining equity base constrain the company’s ability to self-fund clinical development or absorb cost overruns. Structurally this increases execution and dilution risk because meaningful program advancement will likely require external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline expansion — ATX-04 license
The Duke ATX-04 license supplies a late-stage, mechanism-based asset with an existing IND and orphan designation plus human proof-of-concept data. Structurally this diversifies Avenue beyond tramadol, accelerates regulatory path options and strengthens rare-disease program depth.
Read all positive factors
Avenue Therapeutics (ATXI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.81M
Dividend YieldN/A
Average Volume (3M)2.90K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS Growth94.31%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,294,635
10 Day Avg. Volume2,401
30 Day Avg. Volume2,901
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)1.16
Price to Sales (P/S)1.52
P/FCF Ratio-1.16
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-0.74
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avenue Therapeutics Business Overview & Revenue Model
Company Description
Avenue Therapeutics (ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases. The company's core product includes intravenous (IV) tramadol, whi...
How the Company Makes Money
null...
Avenue Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.29M | -11.70M | 4.05M | -2.44M | 7.00K |
| Net Income | -2.91M | -11.65M | -10.38M | -3.55M | -3.73M |
Balance Sheet | |||||
| Total Assets | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.10M | 816.00K | 1.20M | 3.58M | 509.00K |
| Stockholders Equity | 1.83M | 2.80M | 1.58M | 3.90M | 3.45M |
Cash Flow | |||||
| Free Cash Flow | -1.83M | -9.03M | -12.45M | -7.60M | -3.75M |
| Operating Cash Flow | -1.83M | -9.03M | -9.45M | -7.60M | -3.75M |
| Investing Cash Flow | 0.00 | 0.00 | -3.00M | 0.00 | 0.00 |
| Financing Cash Flow | 2.09M | 9.84M | 7.53M | 10.54M | 4.38M |
Avenue Therapeutics Technical Analysis
Positive
0.73
Price Trends
0.28
Positive
0.44
Positive
0.54
Positive
Market Momentum
0.07
Negative
78.80
Negative
83.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATXI, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.37, above the 50-day MA of 0.28, and above the 200-day MA of 0.54, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 78.80 is Negative, neither overbought nor oversold. The STOCH value of 83.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATXI.
Avenue Therapeutics Risk Analysis
Avenue Therapeutics disclosed 57 risk factors in its most recent earnings report. Avenue Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avenue Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.81M | -0.75 | -121.42% | ― | ― | 94.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $2.57M | -0.20 | ― | ― | 99.48% | -474.47% | |
43 Neutral | $1.42M | -0.19 | -63.03% | ― | ― | 88.07% | |
| ― | $2.58M | -0.17 | -168.95% | ― | ― | 83.36% |
* Healthcare Sector Average
ATXI
Avenue Therapeutics
0.61
0.38
164.35%
BDRX
Biodexa Pharmaceuticals
3.03
-67.47
-95.70%
QCLS
Q/C Technologies
3.73
-15.64
-80.74%
SCNI
Scinai Immunotherapeutics
0.71
-2.19
-75.52%
OGEN
Oragenics
0.62
-4.48
-87.84%
Avenue Therapeutics Corporate Events
Business Operations and Strategy
Avenue Therapeutics Licenses ATX-04 for Pompe Disease
Positive
Feb 23, 2026
On February 23, 2026, Avenue Therapeutics announced it had entered an exclusive worldwide license agreement with Duke University covering patents and know-how for ATX-04 (clenbuterol), a selective β2-adrenergic agonist in clinical development...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.